Episurf Medical AB (publ) (EPIS-B.ST)
SEK 0.13
(-2.03%)
SEK 0.13
(-2.03%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 104.3 Million SEK | -47.11% |
| 2022 | 197.2 Million SEK | -27.12% |
| 2021 | 270.6 Million SEK | 45.95% |
| 2020 | 185.4 Million SEK | 221.88% |
| 2019 | 57.6 Million SEK | 5.11% |
| 2018 | 54.8 Million SEK | -41.26% |
| 2017 | 93.28 Million SEK | 54.69% |
| 2016 | 60.3 Million SEK | -48.98% |
| 2015 | 118.2 Million SEK | 173.37% |
| 2014 | 43.23 Million SEK | -43.42% |
| 2013 | 76.42 Million SEK | 173.8% |
| 2012 | 27.91 Million SEK | -44.78% |
| 2011 | 50.54 Million SEK | 348.38% |
| 2010 | 11.27 Million SEK | 835.53% |
| 2009 | 1.2 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 133.6 Million SEK | 62.73% |
| 2024 Q3 | 113.5 Million SEK | -15.04% |
| 2024 Q1 | 82.1 Million SEK | -21.28% |
| 2023 Q4 | 104.3 Million SEK | -18.71% |
| 2023 Q3 | 128.3 Million SEK | -17.12% |
| 2023 Q2 | 154.8 Million SEK | -12.1% |
| 2023 FY | 104.3 Million SEK | -47.11% |
| 2023 Q1 | 176.1 Million SEK | -10.7% |
| 2022 FY | 197.2 Million SEK | -27.12% |
| 2022 Q4 | 197.2 Million SEK | -9.33% |
| 2022 Q3 | 217.5 Million SEK | -8.11% |
| 2022 Q2 | 236.7 Million SEK | -7.25% |
| 2022 Q1 | 255.2 Million SEK | -5.69% |
| 2021 Q1 | 167.7 Million SEK | -9.55% |
| 2021 FY | 270.6 Million SEK | 45.95% |
| 2021 Q3 | 134.6 Million SEK | -11.1% |
| 2021 Q4 | 270.6 Million SEK | 101.04% |
| 2021 Q2 | 151.4 Million SEK | -9.72% |
| 2020 Q3 | 137.2 Million SEK | -9.91% |
| 2020 Q4 | 185.4 Million SEK | 35.13% |
| 2020 FY | 185.4 Million SEK | 221.88% |
| 2020 Q2 | 152.3 Million SEK | 27.13% |
| 2020 Q1 | 119.8 Million SEK | 107.99% |
| 2019 Q1 | 48.4 Million SEK | -11.68% |
| 2019 Q2 | 93.6 Million SEK | 93.39% |
| 2019 Q3 | 75.3 Million SEK | -19.55% |
| 2019 Q4 | 57.6 Million SEK | -23.51% |
| 2019 FY | 57.6 Million SEK | 5.11% |
| 2018 Q2 | 70.4 Million SEK | -13.19% |
| 2018 FY | 54.8 Million SEK | -41.26% |
| 2018 Q4 | 54.8 Million SEK | -1.97% |
| 2018 Q3 | 55.9 Million SEK | -20.6% |
| 2018 Q1 | 81.1 Million SEK | -13.06% |
| 2017 Q3 | 107.9 Million SEK | -12.34% |
| 2017 FY | 93.28 Million SEK | 54.69% |
| 2017 Q4 | 93.28 Million SEK | -13.55% |
| 2017 Q2 | 123.09 Million SEK | -16.07% |
| 2017 Q1 | 146.66 Million SEK | 143.21% |
| 2016 Q3 | 73.05 Million SEK | -16.53% |
| 2016 Q4 | 60.3 Million SEK | -17.45% |
| 2016 FY | 60.3 Million SEK | -48.98% |
| 2016 Q1 | 104.41 Million SEK | -11.66% |
| 2016 Q2 | 87.51 Million SEK | -16.19% |
| 2015 Q4 | 118.2 Million SEK | -9.36% |
| 2015 Q1 | 36.25 Million SEK | -16.16% |
| 2015 FY | 118.2 Million SEK | 173.37% |
| 2015 Q3 | 130.4 Million SEK | 402.15% |
| 2015 Q2 | 25.96 Million SEK | -28.37% |
| 2014 Q1 | 68.08 Million SEK | -10.9% |
| 2014 FY | 43.23 Million SEK | -43.42% |
| 2014 Q4 | 43.23 Million SEK | -13.38% |
| 2014 Q3 | 49.91 Million SEK | -17.36% |
| 2014 Q2 | 60.4 Million SEK | -11.28% |
| 2013 Q2 | 72.45 Million SEK | 217.5% |
| 2013 Q1 | 22.82 Million SEK | -18.24% |
| 2013 Q3 | 81.97 Million SEK | 13.13% |
| 2013 Q4 | 76.42 Million SEK | -6.77% |
| 2013 FY | 76.42 Million SEK | 173.8% |
| 2012 Q2 | 35.06 Million SEK | -10.18% |
| 2012 Q1 | 39.04 Million SEK | -22.75% |
| 2012 FY | 27.91 Million SEK | -44.78% |
| 2012 Q4 | 27.91 Million SEK | -14.41% |
| 2012 Q3 | 32.61 Million SEK | -7.0% |
| 2011 Q3 | 52.44 Million SEK | -6.49% |
| 2011 Q2 | 56.08 Million SEK | 450.31% |
| 2011 Q1 | 10.19 Million SEK | -9.59% |
| 2011 FY | 50.54 Million SEK | 348.38% |
| 2011 Q4 | 50.54 Million SEK | -3.62% |
| 2010 FY | 11.27 Million SEK | 835.53% |
| 2010 Q4 | 11.27 Million SEK | 0.0% |
| 2009 FY | 1.2 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Acarix AB (publ) | 62.88 Million SEK | -65.861% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 96.827% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 96.827% |
| Arcoma AB | 81.96 Million SEK | -27.254% |
| Bactiguard Holding AB (publ) | 682.87 Million SEK | 84.726% |
| BICO Group AB (publ) | 10.19 Billion SEK | 98.977% |
| Boule Diagnostics AB (publ) | 755.1 Million SEK | 86.187% |
| CellaVision AB (publ) | 928.71 Million SEK | 88.769% |
| Clinical Laserthermia Systems AB (publ) | 57.72 Million SEK | -80.684% |
| Chordate Medical Holding AB (publ) | 21.95 Million SEK | -375.052% |
| C-Rad AB (publ) | 404 Million SEK | 74.183% |
| Duearity AB (publ) | 15.14 Million SEK | -588.722% |
| Dignitana AB (publ) | 44.83 Million SEK | -132.652% |
| Getinge AB (publ) | 55.09 Billion SEK | 99.811% |
| Scandinavian Real Heart AB (Publ) | 102.63 Million SEK | -1.619% |
| Iconovo AB (publ) | 128.07 Million SEK | 18.566% |
| Integrum AB (publ) | 164.85 Million SEK | 36.734% |
| Luxbright AB (publ) | 40.68 Million SEK | -156.349% |
| Mentice AB (publ) | 322.52 Million SEK | 67.662% |
| OssDsign AB (publ) | 356.38 Million SEK | 70.734% |
| Paxman AB (publ) | 167.12 Million SEK | 37.592% |
| Promimic AB (publ) | 92.87 Million SEK | -12.301% |
| Qlife Holding AB (publ) | 39.04 Million SEK | -167.121% |
| SciBase Holding AB (publ) | 64.33 Million SEK | -62.123% |
| ScandiDos AB (publ) | 81.47 Million SEK | -28.018% |
| Sectra AB (publ) | 3.21 Billion SEK | 96.752% |
| Sedana Medical AB (publ) | 1.01 Billion SEK | 89.715% |
| Senzime AB (publ) | 433.54 Million SEK | 75.942% |
| SpectraCure AB (publ) | 144.83 Million SEK | 27.987% |
| Stille AB | 804.89 Million SEK | 87.042% |
| Vitrolife AB (publ) | 16.39 Billion SEK | 99.364% |
| Xvivo Perfusion AB (publ) | 2.19 Billion SEK | 95.25% |